SAREPTA THERAPEUTICS, INC. Contract Liability (Deferred Revenue)
SAREPTA THERAPEUTICS, INC. (SRPT) had Contract Liability (Deferred Revenue) of $110.13 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability, Current $110.13M.
- 2026-03-31: Contract with Customer, Liability, Current $116.04M.
- 2025-12-31: Contract with Customer, Liability, Current $443.40M.
- 2025-09-30: Contract with Customer, Liability, Current $485.45M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $110.13M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $116.04M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $443.40M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $485.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $395.43M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $44.86M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $130.26M 10-K · filed 2026-03-02 |
| 2024-09-30 | $127.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $122.04M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $112.00M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $50.42M 10-K · filed 2025-02-28 |
| 2023-09-30 | $22.49M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $44.99M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $67.24M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $89.24M 10-K · filed 2024-02-28 |
| 2022-09-30 | $89.24M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $89.24M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $89.24M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $89.24M 10-K · filed 2023-02-28 |
| 2021-09-30 | $89.24M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $89.24M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $89.24M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $89.24M 10-K · filed 2022-03-01 |
| 2020-09-30 | $89.24M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $89.31M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $91.07M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $3.30M 10-K · filed 2021-03-01 |
| 2019-09-30 | $3.30M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $3.30M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.98M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $3.30M 10-Q · filed 2019-11-07 |
| 2017-12-31 | $3.32M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |